ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Peter Hosein, M.D., a medical oncologist specializing in pancreatic cancer at Sylvester Comprehensive Cancer Center, ...

In recent years, the role of gut microbiota has become the major area of focus in human health and diseases. Numerous studies have highlighted the importance of gut microbiota in the regulation of ...

Dr. Watanabe and his team from Niigata University have revealed that PET/CT image analysis using artificial intelligence (AI) ...

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...